Inpatient cardiology consultation for COVID-19: What are cardiologists' diagnostic approaches?
Open Access
- 1 January 2022
- journal article
- research article
- Published by Medknow in Research in Cardiovascular Medicine
- Vol. 11 (1) , 6-12
Abstract
Aim: Despite concerns about cardiovascular implications in coronavirus disease-2019 (COVID-19) patients, not all COVID-19 patients are visited by cardiologists and recommended to perform comprehensive cardiovascular assessments including measurement of biomarkers and echocardiography. We aimed to investigate the reasons for seeking cardiology care and to assess our cardiologists' diagnostic approaches to COVID-19 patients with potential cardiovascular involvement. Methods and Results: In this prospective, observational study, data of all consecutive COVID-19 patients admitted to six designated hospitals for COVID-19 in Iran in whom bedside cardiology consultation was requested were collected. A total of 148 patients including 105 (71%) males were included. The mean age was 57 ± 17 years. The most common reasons for cardiology consultation were dyspnea (56.7%), chest pain (12.8%), and suspected arrhythmias (10.8%). The most common comorbidities were hypertension (40.5%), diabetes mellitus (19.6%), and coronary heart disease (18.9%). A 12-lead electrocardiography (ECG) was obtained in all patients. Point-of-care ultrasonography or limited transthoracic echocardiography (TTE) was performed in 106 (71.6%) patients, and complete TTE was performed in 35 (23.4%) patients. Cardiac troponin was measured in 63 (42.6%) patients, and N-terminal pro B-type natriuretic peptide level was measured in 34 (23%) patients. Overall, 51 (34.5%) patients underwent invasive mechanical ventilation, inotropes were used in 29 (19.6%) patients, and 40 (27%) patients died. Conclusions: While preventing unnecessary investigations, the cardiologists should not overlook the lifesaving role of ubiquitous diagnostic modalities (such as ECG and TTE) in early detection and management of cardiac involvement in COVID-19.Keywords
This publication has 38 references indexed in Scilit:
- Assessment of acute lung injury/acute respiratory distress syndrome using B-type brain natriuretic peptideJournal of International Medical Research, 2015
- Serum levels of N–terminal proB–type natriuretic peptide in mechanically ventilated critically ill patients – relation to tidal volume size and development of acute respiratory distress syndromeBMC Pulmonary Medicine, 2013
- Prognostic Significance of Elevated Cardiac Troponin-T Levels in Acute Respiratory Distress Syndrome PatientsPLOS ONE, 2012
- Prognostic Utility of Changes in N-Terminal Pro-Brain Natriuretic Peptide Combined with Sequential Organ Failure Assessment Scores in Patients with Acute Lung Injury/Acute Respiratory Distress Syndrome Concomitant with Septic ShockShock, 2011
- N-terminal pro–brain natriuretic peptide as a marker of right ventricular dysfunction after open-lung approach in patients with acute lung injury/acute respiratory distress syndromeJournal of Critical Care, 2011
- Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome*Critical Care Medicine, 2007
- Diagnostic and Prognostic Utility of Brain Natriuretic Peptide in Subjects Admitted to the ICU With Hypoxic Respiratory Failure Due to Noncardiogenic and Cardiogenic Pulmonary EdemaChest, 2007
- Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromesJACC, 2003
- Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patientsThe American Journal of Cardiology, 2002
- Serum Cardiac Troponin T as a Prognostic Marker in Early SepsisChest, 1998